For decades, some cancers were a near-certain death sentence. Now, a new generation of cancer drugs—many coming from biotech, not big pharma—is changing that. RTW’s Chris Liu discusses ASCO 2026, and breakthroughs in pancreatic cancer, lung cancer, and other hard-to-treat tumors. What's driving the progress, why is it happening now, and what does it mean for the future of cancer care?

PODCAST TEAM

Producer & Director: Devon Leaver

Editor: Dominique Guerra

Production Coordinator: Ying Yu Lin

Production Support: Annabelle Chan

Production Assistant: Nicole M. Rosales

Executive Editorial Advisor: Stephanie A. Sirota

Research Consultant: Chris Liu

Research Consultant: Julia Harper

Research Consultant: Lauren Lee

Theme Music: Yehezkel Raz

Additional Music: APM Music

Featuring by Chris Liu, Senior Research Analyst, moderated by Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on YouTube, Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 - Introduction

1:04 – The Evolution of Cancer Treatments

3:19 - Unmet Needs in Oncology

10:03 - Treating Pancreatic Cancer

14:20 - The Importance of ASCO

16:48 - The Rise of Chinese Biotech

21:54 - Trends in Oncology

23:42 - Outro

DISCLAIMER

This interview was given by Chris Liu, Senior Research Analyst, and moderated by Partner, and Chief Business Officer Stephanie Sirota, at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.

Menopause, perimenopause, and hormone replacement therapy (HRT) are reshaping the conversation around women’s health and longevity. OB/GYN Dr. Stephanie Lam explains the science, symptoms, and why women’s healthcare may represent a major investing whitespace.

PODCAST TEAM

Producer & Director: Devon Leaver

Editor: Dominique Guerra

Production Coordinator: Ying Yu Lin

Production support: Annabelle Chan

Executive Editorial Advisor: Stephanie Sirota

Theme music: Yehezkel Raz

Additional music: APM Music

Featuring: Dr. Stephanie Lam, OB/GYN, Carnegie Women’s Health, moderated by Stephanie Sirota, Partner, Chief Business Officer, RTW Investments, LP.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 – Introduction

00:55 - Dr. Lam’s Path to OB/GYN

2:01 - Defining Menopause and Perimenopause

5:05 - The Health Impact of HRT

8:08 - A Holistic View of Women’s Health

10:35 - GLPs and Women’s Healthcare

14:25 - Investment Whitespaces in Women’s Health

19:03 - Outro

DISCLAIMER

This interview was given by Dr. Stephanie Lam, OB/GYN at Carnegie Women’s Health in New York, and moderated by Stephanie Sirota, Partner, Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.

What if you could fix disease by rewriting DNA? From CRISPR to next-gen gene editing, Stephanie Sirota and Beam Therapeutics CEO John Evans break down base editing, prime editing, and the path to one-time cures.

PODCAST TEAM

Producer & Director: Devon Leaver

Editor: Dominique Guerra

Production Coordinator: Ying Yu Lin

Production support: Annabelle Chan

Executive Editorial Advisor: Stephanie Sirota

Research Consultant: Piratip Pratumsuwan

Theme music by: Yehezkel Raz

Additional music: APM Music

Featuring: John Evans, CEO and Board Member of Beam Therapeutics, moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 – Introduction

1:15 – Gene Editing, Gene Therapy, Base and Prime Editing

4:18 – Challenges in Gene Editing

6:09 – In Vivo and Ex Vivo

9:33 – What is A1AT Deficiency?

13:44 – Safety in Gene Editing

15:52 – AI and Beam Therapeutics

21:25 – John Evans’ Journey into Biotech

23:06 – Outro

DISCLAIMER

This interview was given by John Evans, CEO and Board Member of Beam Therapeutics, and moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.